Solutions
Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Obesity Physiology and Biochemistry Analysis Service

Inquiry

Overview of Metabolic Crosstalk in Obesity

Obesity is defined as the excess of adipose tissue resulting from a positive energy balance and is associated with the imbalance between the anabolic and catabolic processes involved in lipid metabolism. The adipose tissue is subdivided into visceral adipose tissue, subcutaneous adipose tissue delimited by the fat deposit in the epidermis, and mesenteric adipose tissue in the double fold of the peritoneum. Some hormones, such as leptin and insulin, are directly involved in the onset and progression of obesity and its associated complications. Leptin, produced in white adipose tissue, acts to control appetite and the amount of body adipose tissue. The accumulation of visceral adipose tissue promotes chronic inflammation grade 1 from the release of pro-inflammatory cytokines and a reduction of anti-inflammatory cytokines. Because obesity is a multifactorial metabolic disorder that promotes biochemical and immunological changes, its prevention and treatment become relevant.

Our Excellence-Driven Service

Protheragen analyzes obesity-related physiological and biochemical changes—including insulin resistance, lipid dysregulation, adipose tissue heterogeneity, and chronic inflammation—to underpin anti-obesity therapy development. By identifying therapeutic targets and validating their roles in preclinical models, we integrate testing services such as insulin sensitivity profiling, lipidomics, and body composition imaging to quantify pathological features, assess drug efficacy, and ensure safety in preclinical studies. Through this synergy, we translate mechanistic insights into actionable therapies.

Decoding Obesity at the Molecular Crossroads: Precision Insights, Personalized Pathways

Obesity drives systemic physiological and biochemical alterations, including insulin resistance, lipid dysregulation, hypertension, and adipose tissue heterogeneity, which collectively elevate risks for diabetes, cardiovascular diseases, and metabolic syndrome. To address these complexities, integrated testing services—insulin testing service, blood lipid testing service, arterial blood pressure testing service, and body mass distribution testing service—provide actionable insights by linking molecular mechanisms to clinical outcomes. These services synergistically enable personalized risk stratification, intervention monitoring, and research into emerging areas like gut microbiota and single-cell omics, advancing precision medicine in obesity management.

Insulin Testing Service

Our insulin testing service integrates chemiluminescent IMA for free/total insulin measurement, C-peptide detection for β-cell function assessment, dynamic OGTT profiling, and hyperinsulinemic-euglycemic clamp techniques, supporting precision obesity research and drug development with gold-standard accuracy.

Blood Lipid Testing Service

We use eco-friendly solvents to extract lipids, isolate key classes via solid-phase extraction, and convert them to analyzable derivatives. Advanced GC-MS quantifies lipid species, identifying obesity-linked metabolic dysregulation. This service supports anti-obesity drug development by revealing therapeutic targets.

Arterial Blood Pressure Testing Service

Protheragen uses implanted catheters and sensors to monitor real-time blood pressure in freely moving animals. This method captures dynamic cardiovascular data in natural conditions while allowing drug administration, aiding obesity-related research and anti-obesity therapy safety/efficacy testing in preclinical studies.

Body Mass Distribution Testing Service

We use MRI to analyze fat distribution in rodent models through standardized protocols. Combining manual segmentation and automated algorithms, it provides high-resolution, longitudinal fat quantification to identify obesity mechanisms, evaluate compartment-specific drug effects, and validate therapeutic targets for anti-obesity therapies in preclinical development.

Applications

  • Our service can be used to identify novel biomarkers (e.g., lipidomic signatures, microRNA profiles) for early diagnosis research.
  • Our service can be used to evaluate obesity-linked comorbidities (e.g., hypertension, dyslipidemia) through integrated arterial pressure monitoring and lipidomics.
  • Our service can be applied to uncover drivers of lipid accumulation and energy imbalance in adipose tissue.

Advantages

  • We integrate multi-dimensional testing services (e.g., insulin sensitivity profiling, lipidomics, body composition imaging) to holistically assess obesity-related pathologies.
  • We bridge mechanistic insights to actionable therapies by validating therapeutic targets in preclinical models.
  • We synergize physiological, biochemical, and immunological analyses to address obesity's multifactorial nature and associated complications.

Publication Data

DOI: 10.3389/fendo.2021.706978

Journal: Frontiers in Endocrinology

Published: 2021

IF: 3.9K

Result: The authors present a comprehensive review on obesity, highlighting its global epidemic status driven by complex interactions between genetic, epigenetic, environmental, and lifestyle factors. They emphasize that obesity arises from long-term energy imbalance but is profoundly influenced by genetic predispositions (e.g., monogenic mutations like MC4R or polygenic traits), epigenetic modifications (DNA methylation, miRNAs), gut microbiome dysbiosis, and obesogenic environments (processed diets, sedentary lifestyles). The review underscores obesity's role in metabolic disorders (diabetes, cardiovascular diseases) and explores therapeutic strategies, including lifestyle modifications, pharmacotherapy (GLP-1 agonists, MC4R agonists), bariatric surgery, and fecal microbiota transplantation. They advocate for integrated approaches combining public health policies (food regulations, sugar taxes), personalized medicine (genetic/epigenetic insights), and microbiome-targeted interventions to address this multifactorial disease and mitigate its global health burden.

Frequently Asked Questions

  1. Are there options for data integration with other omics?

    Yes. The service supports multi-omics integration (e.g., transcriptomics, proteomics, metabolomics) for a systems-level understanding of obesity.

  2. How to ensure data confidentiality?

    All data are handled under strict confidentiality agreements. Client information and results are stored securely with restricted access.

Protheragen's obesity physiology and biochemistry analysis service offers a comprehensive approach to deciphering obesity-related metabolic dysregulation, including insulin resistance, lipid imbalances, adipose tissue heterogeneity, and chronic inflammation. By integrating advanced testing services—such as insulin sensitivity profiling, lipidomics, body composition imaging, and single-cell omics—we identify therapeutic targets, validate drug efficacy in preclinical models. contact us to leverage our expertise in translating complex obesity pathophysiology into actionable therapies.

Reference

  1. Lin, X.; Li, H. Obesity: epidemiology, pathophysiology, and therapeutics. Frontiers in endocrinology. 2021, 12: 706978. (CC BY 4.0)

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions
Inquiry

Copyright © Protheragen. All rights reserves.